These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 36694243)

  • 41. Targeting the Pim kinases in multiple myeloma.
    Keane NA; Reidy M; Natoni A; Raab MS; O'Dwyer M
    Blood Cancer J; 2015 Jul; 5(7):e325. PubMed ID: 26186558
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PIM kinases as therapeutic targets against advanced melanoma.
    Shannan B; Watters A; Chen Q; Mollin S; Dörr M; Meggers E; Xu X; Gimotty PA; Perego M; Li L; Benci J; Krepler C; Brafford P; Zhang J; Wei Z; Zhang G; Liu Q; Yin X; Nathanson KL; Herlyn M; Vultur A
    Oncotarget; 2016 Aug; 7(34):54897-54912. PubMed ID: 27448973
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin.
    Julson JR; Quinn CH; Nazam N; Bownes LV; Stewart JE; Beierle EA
    J Pediatr Surg; 2024 Jul; 59(7):1334-1341. PubMed ID: 38570263
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Pim kinases: new targets for drug development.
    Swords R; Kelly K; Carew J; Nawrocki S; Mahalingam D; Sarantopoulos J; Bearss D; Giles F
    Curr Drug Targets; 2011 Dec; 12(14):2059-66. PubMed ID: 21777193
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies].
    Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN
    Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
    Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
    Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Insulin receptor substrate 1 is a substrate of the Pim protein kinases.
    Song JH; Padi SK; Luevano LA; Minden MD; DeAngelo DJ; Hardiman G; Ball LE; Warfel NA; Kraft AS
    Oncotarget; 2016 Apr; 7(15):20152-65. PubMed ID: 26956053
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
    Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
    Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Topical advances in PIM kinases and their inhibitors: Medicinal chemistry perspectives.
    Walhekar V; Bagul C; Kumar D; Muthal A; Achaiah G; Kulkarni R
    Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188725. PubMed ID: 35367531
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of PIM Kinases Promotes Neuroblastoma Cell Differentiation to a Neuronal Phenotype.
    Julson JR; Quinn CH; Bownes LV; Hutchins SC; Stewart JE; Aye J; Yoon KJ; Beierle EA
    J Pediatr Surg; 2023 Jun; 58(6):1155-1163. PubMed ID: 36907773
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The survival kinases Akt and Pim as potential pharmacological targets.
    Amaravadi R; Thompson CB
    J Clin Invest; 2005 Oct; 115(10):2618-24. PubMed ID: 16200194
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of PIM kinases in human and mouse CD4+ T cell activation and inflammatory bowel disease.
    Jackson LJ; Pheneger JA; Pheneger TJ; Davis G; Wright AD; Robinson JE; Allen S; Munson MC; Carter LL
    Cell Immunol; 2012; 272(2):200-13. PubMed ID: 22078270
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia.
    Joglekar T; Chin A; Voskanian-Kordi A; Baek S; Raja A; Rege A; Huang W; Kane M; Laiho M; Webb TR; Fan X; Rubenstein M; Bieberich CJ; Li X
    Blood Adv; 2024 Aug; 8(15):3880-3892. PubMed ID: 38739710
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells.
    Siu A; Virtanen C; Jongstra J
    Oncotarget; 2011 Dec; 2(12):1134-44. PubMed ID: 22193779
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structure-based design of low-nanomolar PIM kinase inhibitors.
    Ishchenko A; Zhang L; Le Brazidec JY; Fan J; Chong JH; Hingway A; Raditsis A; Singh L; Elenbaas B; Hong VS; Marcotte D; Silvian L; Enyedy I; Chao J
    Bioorg Med Chem Lett; 2015 Feb; 25(3):474-80. PubMed ID: 25575657
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Feedback Loop Regulation between Pim Kinases and Tax Keeps Human T-Cell Leukemia Virus Type 1 Viral Replication in Check.
    Bellon M; Nicot C
    J Virol; 2022 Feb; 96(3):e0196021. PubMed ID: 34818069
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors.
    Mikkers H; Nawijn M; Allen J; Brouwers C; Verhoeven E; Jonkers J; Berns A
    Mol Cell Biol; 2004 Jul; 24(13):6104-15. PubMed ID: 15199164
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors.
    Wurz RP; Sastri C; D'Amico DC; Herberich B; Jackson CLM; Pettus LH; Tasker AS; Wu B; Guerrero N; Lipford JR; Winston JT; Yang Y; Wang P; Nguyen Y; Andrews KL; Huang X; Lee MR; Mohr C; Zhang JD; Reid DL; Xu Y; Zhou Y; Wang HL
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5580-5590. PubMed ID: 27769621
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PIM3 Kinase: A Promising Novel Target in Solid Cancers.
    Atalay P; Ozpolat B
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339286
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition.
    Iqbal A; Eckerdt F; Bell J; Nakano I; Giles FJ; Cheng SY; Lulla RR; Goldman S; Platanias LC
    Oncotarget; 2016 May; 7(22):33192-201. PubMed ID: 27120806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.